fda warning letter compounding semaglutide october 2025 letters alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products FDA warns consumers not to – Novo Nordisk Calls for FDA

At the same time, a 2025 systematic review and meta-analysis found that GLP-1 receptor agonists actually increased total testosterone, luteinizing hormone, and follicle-stimulating hormone levels in men with overweight or obesity

Understanding proper injection site selection is essential for medication efficacy, patient comfort, and minimizing adverse reactions

Canonical Nlrp3 Inflammasome links systemic low-grade inflammation to functional decline in aging

Because they are partners in your weight loss journey to achieve the healthiest long-term results We examine the pros and cons of GLP-1s and the factors contributing to safer and healtier weight loss